GoodRx Holdings, Inc. said certain financial statements should no longer be relied upon after revenue recognition errors undercounted Pharma Direct revenue. It delayed its quarter ended September 30, 2026 filing and expects one or more material weaknesses in internal controls.
GDRX · GoodRx Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
GoodRx Holdings, Inc. said statements for periods ended March 31, 2026 and June 30, 2026 should no longer be relied upon due to understated Pharma Direct revenue. Amended filings are planned, and material weaknesses in internal control are expected.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. GoodRx reported Q2 revenue of $200.4 million, down 1% year-over-year, as Pharma Direct (+76%) and Subscription (+39%) growth was offset by a 26% drop in prescription transactions revenue and a CFO transition; the company raised its full-year 2026 revenue outlook to $790–$805 million and Adjusted EBITDA to $240–$250 million.
- + Pharma Direct revenue grew 76% year-over-year to $61.6 million, with full-year PharmaDirect now expected to grow more than 70%.
- + Subscription revenue grew 39% year-over-year to $28.5 million and subscription plans rose 14%, supported by the May launch of GoodRx Companion.
- + Company raised full-year 2026 Adjusted EBITDA guidance to $240–$250 million.
- + Net cash provided by operating activities rose to $80.8 million in Q2 from $49.6 million a year earlier, with $296.1 million of cash on hand.
- − Total revenue declined 1% year-over-year to $200.4 million.
- − Prescription transactions revenue fell 26% year-over-year to $106.4 million on declining MACs and deliberate shift toward subscriptions.
- − Net income declined to $8.5 million from $12.8 million and Adjusted Net Income fell to $26.8 million from $33.9 million.
- − Adjusted EBITDA margin contracted to 31.8% from 34.2% as Adjusted EBITDA fell to $63.7 million from $69.4 million.
- − CFO transition: Chris McGinnis departed as CFO and was replaced by Justin Fingler, adding leadership risk during a business model pivot.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings Per Share non-GAAP | $0.08 | Three Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $122.01M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 30.9% | Six Months Ended June 30, 2026 | — |
| Adjusted Net Income non-GAAP | $49.83M | Six Months Ended June 30, 2026 | — |
| Adjusted Net Income Margin non-GAAP | 12.6% | Six Months Ended June 30, 2026 | — |
| Monthly Active Consumers | 5M | Three Months Ended June 30, 2026 | — |
| Subscription plans | 764K | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GDRX
this stock
GoodRx Holdings, Inc.
|
$1.15B | +24.0% | +0.6% | 84.0 | 1.0% |
|
VEEV
Veeva Systems Inc
|
$44.88B | +24.2% | +28.1% | 45.4 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$13.60B | +82.5% | +28.2% | 37.1 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$11.60B | +7.7% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 19
GoodRx Holdings, Inc. said certain financial statements should no longer be relied upon after revenue recognition errors undercounted Pharma Direct revenue. It delayed its quarter ended September 30, 2026 filing and expects one or more material weaknesses in internal controls.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GDRX | -8.0% | -5.9% | +15.1% | -3.7% | +24.0% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -4.1% | -0.3% | +18.5% | -0.3% | +16.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.